Status:
COMPLETED
COMETS - Compare the Efficacy of Rosuvastatin With Atorvastatin and Placebo in the Treatment of Non-Diabetic, Non-Atheroscleric, Metabolic Syndrome Subjects
Lead Sponsor:
AstraZeneca
Conditions:
Metabolic Syndrome
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the efficacy of treatment with rosuvastatin with atorvastatin in reducing Low density lipoprotein cholesterol over 6 weeks of treatment in subjects with metabol...
Eligibility Criteria
Inclusion
- Presence of 3 or more coronary heart disease risk factors as defined by the protocol.
- Fasting low density lipoprotein cholesterol level of \> 130 mg/dL.
- Documented history of, or high risk of coronary heart disease or other established atherosclerotic disease.
- Not previously taken statins.
Exclusion
- The use of lipid lowering drugs or dietary supplements after Visit 1
- Active arterial disease eg Unstable angina, or recent arterial surgery
- Blood lipid levels above the limits defined in the protocol
- Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse
Key Trial Info
Start Date :
May 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2005
Estimated Enrollment :
940 Patients enrolled
Trial Details
Trial ID
NCT00654485
Start Date
May 1 2002
End Date
February 1 2005
Last Update
March 16 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.